CANTA.ST Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (24 Apr 2024 @ 11:29):

Stats
Today's Volume	285 166
Average Volume	571 882
Market Cap	596.15M
EPS	SEK0 ( 2024-02-21 )
Next earnings date	( SEK0 ) 2024-05-21
Last Dividend	SEK0 ( N/A )
Next Dividend	SEK0 ( N/A )
P/E	-1.610
ATR14	SEK0.00900 (0.25%)

Volume Correlation

Long: -0.07 (neutral)

Short: -0.66 (moderate negative)

Signal:(44.978) Neutral

Cantargia AB (publ) Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Cantargia AB (publ) Correlation - Currency/Commodity

-0.17
( neutral )

0.16
( neutral )

0.00
( neutral )

-0.25
( neutral )

-0.16
( neutral )

0.26
( neutral )

Cantargia AB (publ) Financials

Annual	2023
Revenue:	SEK0
Gross Profit:	SEK-3.45M (0.00 %)
EPS:	SEK-1.650

Q4	2023
Revenue:	SEK0
Gross Profit:	SEK-863 000 (0.00 %)
EPS:	SEK-0.400

Q3	2023
Revenue:	SEK0
Gross Profit:	SEK-863 000 (0.00 %)
EPS:	SEK-0.460

Q2	2023
Revenue:	SEK0
Gross Profit:	SEK-863 000 (0.00 %)
EPS:	SEK-0.340

Financial Reports:

No articles found.

Cantargia AB (publ)

Cantargia AB (publ), a biotechnology company, engages in the research and development of antibody-based treatments for life threatening diseases. The company is developing CAN04, an antibody against Interleukin-1 Receptor Accessory Protein (IL1RAP) to recognize cancer cells and stimulate natural immune system to destroy such cells, as well as block the tumor inflammation that is driven by the Interleukin-1 system and is under phase IIa clinical trial; and CAN10, an antibody against IL1RAP for treatment of autoimmune and inflammatory diseases, including systemic sclerosis and myocarditis, and is under preclinical trial. It is also developing CANxx antibodies against IL1RAP. The company has collaboration agreements with Patheon Biologics BV and BioWa Inc. for the manufacture and production of CAN04; and Specialized Medical Services-oncology BV for the clinical study of CAN04. Cantargia AB (publ) was founded in 2010 and is based in Lund, Sweden.